Bullish Charts - FDA Grants Orphan Drug Designation for LymphomaMiragen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high-unmet medical need. Its four lead product candidates include cobomarsen, an inhibitor of miR-155 for treating various blood cancers, such as cutaneous T-cell lymphoma, adult T-cell lymphoma/leukemia, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia; Remlarsen, a replacement for miR-29, a microRNA that is found at abnormally low levels in various pathological fibrotic conditions, including cutaneous and ocular fibrosis, which is in Phase II clinical trial; MRG-229, which is in preclinical trial for the treatment of idiopathic pulmonary fibrosis; and MRG- 110, an inhibitor of miR-92, a microRNA expressed in endothelial cells, which has completed two Phase I clinical trial for the treatment of heart failure, wound healing, and other ischemic disease in the United States and Japan. Miragen Therapeutics, Inc. was founded in 2006 and is based in Boulder, Colorado.
LATE BREAKING NEWS AFTER HOURS - POSSIBLY A BIG SPIKE IN THE MORNING
miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that the Food & Drug Administration (FDA) has granted orphan drug designation to cobomarsen, for the treatment of T-cell lymphoma.
DAILY CHART IS BULLISH
OBV is Bullish
MACD turned up Bullish
RSi crossed center line and turned up, Bullish
PMO is turning up, Bullish
This little stock could spike hard.
Best of luck everyone!
DISCLAIMER
The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
Ichimoku_trader
AUDUSDopened position when blue line crossed red line,cluod changed to green and lagging span crossed cloud upwards
Bullish Charts - Vaccine Reduced COVID-19 into Common ColdAbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the United States, Japan, Germany, Canada, France, Spain, Italy, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides SYNAGIS that protects at-risk infants from severe respiratory disease; KALETRA, a prescription anti-HIV-1 medicine; CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; and Lupron, a product for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; and Sevoflurane, an anesthesia product. It has collaborations with Calico Life Sciences LLC; Alector, Inc.; Janssen Biotech, Inc.; Jacobio Pharmaceuticals; and Genmab A/S. The company was incorporated in 2012 and is based in North Chicago, Illinois.
On 07/15/20, Researchers said AbbVie's Tricor reduced severity of COVID-19 into "NOTHING WORSE THAN A COLD."
www.yahoo.com
In my opinion, a vaccine doesn't get any better than this. AbbVie has the vaccine!
Where is all the great news about Tricor killing COVID-19.???
If the stock can break through around $107, I think it's going to spike hard!
The daily chart looks great.
Long!
DISCLAIMER
The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
Bullish Charts - Robust Earnings, Electric Vehicle TechnologiesGarrett Motion Inc. designs, manufactures, and sells turbocharger and electric boosting technologies for light and commercial vehicle original equipment manufacturers and the aftermarket worldwide. The company offers light vehicle gasoline and diesel, and commercial vehicle turbochargers. Its integrated vehicle health management tools detect intermittent faults and anomalies to provide understanding of the real-time health of a vehicle system. The company offers its products through distribution networks. Garrett Motion Inc. was incorporated in 2018 and is headquartered in Rolle, Switzerland.
Daily Chart looks great!
Volume, Bullish
PMO, Bullish
MACD, Bullish
RSI, Bullish
Stochastic, Bullish
On Balance Trending Up, Bullish
Accumulation Trending Up, Bullish
It looks like the stock price broke out above the cloud at or around the $5.73 range.
On 05/11/20, the company announced a huge spike in EPS.
Q1 EPS $0.91, Sales $745.000 Million, Beat $664.040 Million Wall Street Estimates
This one sentence sums up why the company is seeing a surge in revenue and earnings...
"Garrett Motion Inc. designs, manufactures, and sells turbocharger and electric boosting technologies for light and commercial vehicle original equipment manufacturers and the aftermarket worldwide. "
The electric vehicle industry is red hot!
Long!
DISCLAIMER
The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
Bullish Charts - COVID-19 VaccineGilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases. It also provides Yescarta, a chimeric antigen receptor T cell therapy for adult patients with relapsed or refractory large B-cell lymphoma; Zydelig, a kinase inhibitor; Letairis, an oral formulation of an endothelin receptor antagonist for pulmonary arterial hypertension; Ranexa, a tablet to treat chronic angina; and AmBisome, an antifungal agent to treat serious invasive fungal infections. In addition, the company offers its products under the name Cayston, Emtriva, Hepsera, Sovaldi, and Tybost. Further, it develops product candidates for the treatment of viral diseases, inflammatory and fibrotic diseases, and oncology. The company markets its products through its commercial teams; and in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company; Janssen Sciences Ireland UC; Japan Tobacco Inc.; Galapagos NV; Second Genome; Gadeta; Carna Biosciences Inc.; Nurix Therapeutics, Inc.; Humanigen, Inc.; Kiniksa Pharmaceuticals, Ltd.; Kyverna Therapeutics, Inc.; Glympse Bio, Inc.; Renown Institute for Health Innovation; Goldfinch Bio, Inc.; Insitro, Inc.; Novo Nordisk A/S; Yuhan Corporation; Kite Pharma, Inc.; oNKo-innate Pty. Ltd.; and Roche Holding AG. The company has partnership with Arcus Biosciences, Inc. to co-develop and co-commercialize next-generation cancer immunotherapies. Gilead Sciences, Inc. was founded in 1987 and is headquartered in Foster City, California.
On 07/11/20, Gilead announced its drug Remdesivir can reduce risk of death in COVID-19 patients.
On 07/10/20, Former FDA Commissioner Scott Gottlieb said Remdesivir data showed improved COVID-19 Recovery & Reduced Risk of Death by 62%.
The COVID-19 drug alone could be a huge revenue boom for Gilead into the future as many countries stockpile & use it.
On the Daily Chart, it looks to me like a Pennant has formed with a breakout coming, Bullish
Volume, Bullish
PMO, Bullish
MACD, Bullish
RSI, Bullish
OBV, Bullish
Long!
DISCLAIMER
The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
Bullish Industry - Protective Gear, N95 Masks, Robust EarningsAlpha Pro Tech, Ltd., together with its subsidiaries, engages in developing, manufacturing, and marketing a line of disposable protective apparel and infection control, and building supply products in the United States and internationally. The company operates through two segments, Building Supply and Disposable Protective Apparel. The Building Supply segment offers construction weatherization products, such as house wrap, synthetic roof underlayment, and other woven materials. The Disposable Protective Apparel segment provides shoecovers, bouffant caps, gowns, coveralls, lab coats, hoods, and frocks, as well as face masks and face shields. The company provides its products under the Alpha Pro Tech brand name, as well as under private labels. Its products are used primarily in cleanrooms; industrial safety manufacturing environments; health care facilities, such as hospitals, laboratories, and dental offices; pharmaceutical markets; and building and re-roofing sites. The company distributes its products through a network of purchasing groups, distributors, and independent sales representatives, as well as through its sales and marketing force. Alpha Pro Tech, Ltd. was founded in 1983 and is headquartered in Markham, Canada.
On 06/25/20, Alpha Pro announced it will join the Russell 2000 and Russell 3000 Indexes.
The company is also currently included in the Russell Microcap Index.
On 06/23/20, Business Wire announced Aplha Pro serves a $15 Billion dollar Worldwide industry.
On 05/06/20, Alpha Pro announced ROBUST earnings that blew away Wall Street estimates.
Q1 EPS $0.39 up from $0.09 YoY.
In addition, Alpha Pro had 16% growth in its Building Supply segment.
The company has experienced a SURGE in customer demand for its "Proprietary" N-95 Particulate Respirator face mask and other PPE products as a result of the pandemic.
As of May 1, 2020, the company has approx. $46.8 million in orders for the N-95 mask alone.
Alpha Pro has also experienced a robust demand for its "Face Shield" products with orders totaling $13.3 Million as of May 1, 2020.
Alpha Pro ended the 1st qtr of 2020 with working capital of $31.6 million and a current ration of a solid 4:1 - (Bullish Ratio - Strong Cash Position)
The company currently has NO OUTSTANDING DEBT and an unused $3.5 million credit line.
With the recent uptick in COVID-19 infections, more and more states are requiring masks for all activities especially for frontline employees.
The need for Alpha Pro products is not going away anytime soon. Rapid Growth should continue far into 2021 and beyond.
Long!
DISCLAIMER
The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
EUR/USD 4H Ichimoku Analysis.Looks like more downside is coming!If you like my ideas and the work I do, please check out the links in the signature and give me a like ;).
Looks like there is more downside coming as on the 4 hour everything aligns in the Ichimoku system for more downside.
1. Price is under the cloud
2. The Cloud ahead is turning bearish.
3. The Tenkan ( Yellow Line ) is under the Kijun ( Dark Blue line )
4. The Lagging span ( Purple line ) is also under prices and the cloud with no obstacles ahead.
All pointing to more downside. The probabilities are in your favor in this trade opportunity as you can not get more confirmation then this in the Ichimoku system.
Please be carefull and manage your risk on leverage trading!
MANA/BTC Symmetrical Triangle Breakout! Ichimoku Daily AnalysisIf you like my ideas and the work I do, please check out the links in the signature and give me a like ;).
MANA had been forming a symmetrical triangle in the last couple of weeks since it had the first push up.
It now bounced off the Pivot and broke through the top of the Triangle and through R1. If it now finds support on top of the Triangle the trend is confirmed.
On the Ichimoku the Tenkan ( Yellow Line ) Bounced off the Kijun ( Dark Blue Line ) which means it's trading above it and this is a confirmation of the bullish trend.
The RSI shows a slight Bearish Divergence and is somewhat overbought, so I do expect it to come down a bit at least to retest the top of the triangle as support. And there we can see if it holds and get a good entry point.
JPY Shows Strength On H1 Time ChartThe above chart shows the hourly ichimoku cloud of FXCM's JPY index - JPYBASKET. The observations are as follows:
- The lime green leading span A had crossed above the red leading span B.
- The forward cloud is light green and indicates support.
- Price is above the black base line and the base line is moving in a bullish direction.
- The orange lagging span is above price, which is indicative of strength.
These observations suggest an element of bullishness for FXCM's JPYBASKET.
USD/JPY 4H Ichimoku analysisUSD/JPY looks like it might be up for a reversal.
It still looks bearish at the moment, and will until it breaks the Kijun ( Dark Blue Line ) although it does show some bullish signs like the twist in the cloud above as a weak point of resistance ( Green circle ).
Additionally, there is also an increase in volume on the OBV which supports the small uptrend.
If you like my ideas and the work I do, please check out the links in the signature and give me a like ;).
XMR/BTC 4H Ichimoku and chart pattern align for a move!XMR/BTC looks like it's getting to the end of the ascending triangle pattern it has been forming for the last week.
The Tenkan ( Yellow line ) also broke through the Kijun ( Dark blue line ) just a couple candles back and if it breaks the upside of the pattern the next real resistance is 20% to the upside at 0,008 ( Horizontal dotted line ).
If you like my ideas and the work I do, please check out the links in the signature ;).
SPX Prediction | Ichimoku Cloud Calc. (E.g., "Kumo-Ni")The 2nd cloud in the Ichimoku indicator (composed of the Base Line and Conversion Line) tells us that * when the price enters the range, it's bound for change. * S&P500 recently rallied. Now it's settling down according to these cloud calculations.
docs.google.com
TRON/BTC Good entry possible with low risk -Daily Ichimoku SetupTRON/BTC is looking strong trading above the 50/100 EMA.
The Tenkan ( Dark Yellow Line ) Broke above the Kijun ( Dark Blue Line ) and then went on to break the cloud. Now it's retracing from a rejection of the 200 EMA.
Will likely try to break the 200 EMA ( Horizontal 2 ) again.
With the SSB ( Horizontal 1 ) as good support and invalidation if it breaks down that and even more if it breaks the Kijun.
If it breaks the 200 EMA resistance it has good upside potential!
---------
This is not financial advice, manage your risk, and trade carefully!
For a 6 month 10% Discount in fees on BITMEX you can use the link below:
www.bitmex.com
For a 5% Discount in fees on Binance you can use the link below:
www.binance.com
ADA/M20 (ADA/BTC) Ichimoku 4H possible short ideaADA/M20 Has been doing very well the last week and might very well continue, but some signs point to a short term retraction.
On the 4H Chart it seems to have formed a small double top and the Tenkan ( yellow line ) broke the Kijun ( Dark Bleu line ) down which points to a short term bearish movement ( right red circle ).
The lagging Span ( purple line ) also gave some confirmation by breaking through the previous prices ( left red circle ).
The cloud is thick though which points to strong support and so we need confirmation by breaking the horizontal 1 Kijun with the lagging span and then we could see it test the bottom of the cloud SSB ( red line ) at the horizontal 2 which is a nice move on a leveraged trade.
This is not financial advice, manage your risk, and trade carefully!
For a 6 month 10% Discount in fees on BITMEX you can use the link below:
www.bitmex.com
A Nice Entry PointBITSTAMP:BTCUSD shows a good entry point on 4H which the price and the chikou span closed above both the cloud, tenkan, and kijun line. A perfect bullish sign with moderate to low risk, but it's a fair exchange with early moves to catch a good profit. MACD also shows a good momentum on this signal provides even more higher confidence that the price indeed is bullish. Continuation of this pattern will be reflected on 1D charts which is a perfect signal of the bullish sentiment, which in turn will be reflected in 1W charts which is also a perfect signal of 2017 bull run will make its attempt to reappear.
For exit strategy always checks if the price on 1D closes below the kijun / slow line and the MACD shows negative value while doing so.
This is a personal analysis, not meant as any kind of financial advise.
GBPCAD Type 1 Breakout + 81 PIp PotentialPrice is below the Daily, 60 and 15 KS as well as the cloud. All of our 4 Horseman are aligned. This is a Type 1 trade with a High probability and good RRR.
BO Entry = 1.7201
Stop = 1.7226
Risk = 25 pips
Profit target = 1.7120 (the daily projected low)
Reward = 81 Pips
RRR = 3.2 - 1
I would appreciate if you leave a comment or like as a thank you
Allen
Cloud Marking Bullish for SPYSPY has turned bullish and should hold above 278 during this market consolidation based on solid Span B that has been tested and held. Based on futures markets, we could see an opening tomorrow (5/7/2020) around the low 283 mark. Assuming no crazy news comes out tomorrow to drive markets back down to test the 278 level we should see prices rise to the 287 levels which will put us solidly in the 38% fib extension level. Getting the price above the daily Tenkan we could see 291 on Friday. I don't expect any kind of crazy rallies though (unless something big happens in the pharma world) with implied volatility falling to 0.31.
With many states freeing up their economies we should continue to see the bull market, though it won't be explosive it would take a serious blow to get us into bear territory again (at least as far as cloud trading is concerned)
Game plan would be to do some OTM put verticals in the low 280 mark and pick up some long call options. I refuse right now to hold beyond the weekend (call me crazy) so May 8th contracts are my play but your risk profile may allow for farther out contracts.
Also planning on going long on some /ES futures. Will watch how the market runs over night but game planning a buy in at the TK cross on the 15 min chart which looks like will be in the 2850 range and will hold through 2865 with stop at 2840.
